<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138060</url>
  </required_header>
  <id_info>
    <org_study_id>COLOGEN</org_study_id>
    <nct_id>NCT00138060</nct_id>
  </id_info>
  <brief_title>Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants</brief_title>
  <official_title>Protocole Evaluant Chez Des Patients Porteurs de Cancers Colorectaux Metastatiques l'Interet Des Determinants Genotypiques Pour l'Optimisation de l'Efficacite et de la Tolerance de la Chimiotherapie Par Irinotecan et 5-fluorouracile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche Clinique sur les Cancers et le Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche Clinique sur les Cancers et le Sang</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to optimize a fluorouracil/irinotecan chemotherapy regimen by the
      identification of individual thymidylate synthase (TS) and UDP-glucuronosyltransferase 1
      (UGT1A1) polymorphisms before the first administration.

      The results of this identification determine the chemotherapy type: high-dose irinotecan or
      not.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response rate</measure>
    <time_frame>during the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>during the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>during the first administration</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">71</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>180 mg/m² or 260 mg/m² in 90 minutes every 15 days</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 fluorouracil</intervention_name>
    <description>400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has provided written informed consent prior to study-specific screening procedures,
             with the understanding that the patient has the right to withdraw from the study at
             any time without prejudice

          -  Ages between 18 and 85 years

          -  Histologically confirmed colorectal cancer

          -  No treatment for metastatic disease

          -  No irinotecan previously administered

          -  World Health Organization (WHO) performance status &lt; 3

          -  Laboratory values :

               -  neutrophils &gt; 1.5 x 10^9/L;

               -  platelet count &gt; 100 x 10^9/L;

               -  serum creatinine &lt; 130µmol/L;

               -  serum bilirubin &lt; 2 x upper limit of normal (ULN);

               -  ASAT and ALAT &lt; 2.5 x ULN;

               -  alkaline phosphatase &lt; 5 x ULN.

          -  At least one measurable lesion by Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria

        Exclusion Criteria:

          -  History of another malignancy except cured basal cell carcinoma of the skin or
             carcinoma in situ of the uterine cervix, breast or bladder.

          -  Other concomitant anticancer therapy.

          -  Pregnant or lactating women.

          -  Women of childbearing potential unless using a reliable and appropriate contraceptive
             method.

          -  Symptomatic cerebral or leptospiral metastasis.

          -  Intestinal obstruction.

          -  Uncontrolled seizures (diabetes, severe infection).

          -  Clinically significant cardiac disease.

          -  Central nervous system disorders or severe psychiatric disability.

          -  Participation in any investigational study within 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Freyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, CHLS, 69310 Pierre Benite, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, CHU</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, IPC</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, CHLS</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology - CHLS</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, ICL</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2(1):43-7.</citation>
    <PMID>11990381</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>July 19, 2010</last_update_submitted>
  <last_update_submitted_qc>July 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gilles Freyer</name_title>
    <organization>IRCCSang</organization>
  </responsible_party>
  <keyword>genotypic profile</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

